Scholarlink

Objective <p>To compare neurodevelopmental outcomes using Bayley Scales of Infant Development (BSID), between encephalopathic neonates undergoing therapeutic hypothermia (TH), sedated with either continuous dexmedetomidine or intermittent morphine.</p> Study design <p>Retrospective, observational cohort study including encephalopathic neonates born between 2014 - 2022 that underwent TH at two Regional Perinatal Centres, and completed neurodevelopmental follow-up assessments.</p> Results <p>There were no significant differences in demographics or short-term neurologic outcomes between morphine (<i>n</i> = 30) and dexmedetomidine (<i>n</i> = 32) groups. At 12 months, median motor composite scores (104 vs 98.5, <i>p</i> = 0.02) and median fine motor scaled scores (SS) (11 vs 10, <i>p</i> = 0.01) were significantly higher in the dexmedetomidine group. Median expressive language SS were slightly higher in the morphine group (11 v 10, <i>p</i> = 0.05). BSID scores at 18–24 months were similar.</p> Conclusion <p>This study supports the use of dexmedetomidine as first-line sedation agent during TH, given comparable 18–24 month neurodevelopmental outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The effect of using dexmedetomidine versus morphine as sedation on long-term neurodevelopmental outcomes of encephalopathic neonates undergoing therapeutic hypothermia

  • 期刊论文

  • 发表日期：

    2025年2月20日

查看全文
  • Tatiana A. Nuzum,
  • Sadaf H. Kazmi,
  • Elena V. Wachtel

摘要

Objective

To compare neurodevelopmental outcomes using Bayley Scales of Infant Development (BSID), between encephalopathic neonates undergoing therapeutic hypothermia (TH), sedated with either continuous dexmedetomidine or intermittent morphine.

Study design

Retrospective, observational cohort study including encephalopathic neonates born between 2014 - 2022 that underwent TH at two Regional Perinatal Centres, and completed neurodevelopmental follow-up assessments.

Results

There were no significant differences in demographics or short-term neurologic outcomes between morphine (n = 30) and dexmedetomidine (n = 32) groups. At 12 months, median motor composite scores (104 vs 98.5, p = 0.02) and median fine motor scaled scores (SS) (11 vs 10, p = 0.01) were significantly higher in the dexmedetomidine group. Median expressive language SS were slightly higher in the morphine group (11 v 10, p = 0.05). BSID scores at 18–24 months were similar.

Conclusion

This study supports the use of dexmedetomidine as first-line sedation agent during TH, given comparable 18–24 month neurodevelopmental outcomes.